November 14, 2023 – FDA OKs PD-L1 pharmDx for Gastric and GEJ Cancer

The PD-L1 IHC 22C3 pharmDx companion diagnostic tool is now FDA-approved to aid in the identification of patients with gastric or GEJ adenocarcinoma for whom pembrolizumab is a suitable treatment, according to Agilent Technologies, the device’s manufacturer.1

Read more>